Home > Insider Trading > Filing (0001179110-21-000539)

Filing Details

Accession Number:: 0001179110-21-000539
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-12 16:17:12
Reporting Period:: 2021-01-08

Accepted Time:: 2021-01-12 16:17:12
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1070081	Ptc Therapeutics Inc.	PTCT	Pharmaceutical Preparations (2834)	043416587

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1808968	B. Matthew Klein	C/O Ptc Therapeutics, Inc. 100 Corporate Court South Plainfield NJ 07080	Chief Development Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-01-08	5,500	$38.98	24,809	No	4	M	Direct
Common Stock	Disposition	2021-01-08	4,000	$69.48	20,809	No	4	S	Direct
Common Stock	Disposition	2021-01-08	1,500	$70.32	19,309	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-01-08	5,500	$38.98	5,500	$38.98

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
90,614		2029-10-24	No	4	M	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (Right to Buy)	$66.49		2031-01-05	52,500	52,500	Direct
Common Stock	Stock Option (Right to Buy)	$47.49		2030-04-15	50,000	50,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2031-01-05	52,500	52,500	Direct
2030-04-15	50,000	50,000	Direct

Footnotes

This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 2, 2020.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $68.98 to $69.93 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $70.00 to $70.61 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This option was granted on October 25, 2019, and vests over four years, with 25% of the shares underlying the option vesting on October 28, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on January 28, 2021.
This option was granted on April 16, 2020, and vests over four years, with 25% of the shares underlying the option vesting on April 16, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on July 16, 2021.
This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.